Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxide in Myocardial Infarction Size

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myocardial infarction and electrocardiographic evidence of ST elevation~* No clinical evidence of congestive heart failure~* All patients must undergo successful percutaneous coronary intervention for thrombolysis in myocardial infarction (TIMI) 0 or 1 coronary flow with resulting TIMI 2 or 3 flow~* Greater than 18 years of age~* Signed Institutional Review Board (IRB) approved informed consent~Exclusion Criteria:~* Prior myocardial infarction~* Requirement for urgent cardiac surgery~* Previous coronary artery bypass graft (CABG) or primary coronary intervention (PCI)~* Left bundle branch block~* Heart block that is expected to require a temporary pacemaker for greater than 72 hours~* Prior use of thrombolytic therapy for the current event~* Unable to tolerate magnetic resonance imaging or unable to tolerate gadolinium contrast media, including patients with a calculated creatinine clearance less than 60 ml/min/1.73m² Body Surface Area (BSA)~* Active or recent hemorrhage requiring an invasive procedure for evaluation or transfusion within 6 weeks prior to presentation, or hemorrhagic stroke within the 6 weeks prior~* Neutropenia (WBC \<2000 (mm)³), Anemia (HCT \<30%, Thrombocytopenia (Thrombocytes \<50,000 (mm)³). It is not necessary to confirm blood counts prior to start of study drug in the absence of clinical suspicion.~* Known or suspected aortic dissection.~* Prior history of pulmonary disease requiring chronic oxygen therapy.~* Pregnancy, lactating, and women of childbearing potential.~* Medical problem likely to preclude completion of the study.~* Use of investigational drugs or device within the 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled Nitric Oxide (Type: EXPERIMENTAL): Inhaled Nitric oxide administered at 80 parts per million (ppm)
- Placebo (Type: PLACEBO_COMPARATOR): Inhaled nitrogen gas (Placebo) administered at 80 ppm

Based on this trial design, predict the completion outcome and termination type (if applicable).